These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 36755360)

  • 1. Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once-boosted BA.1/2 convalescents and twice-boosted COVID-19-naïve individuals.
    Kang CK; Kim MG; Park SW; Kim YW; Lee CM; Choe PG; Park WB; Kim NJ; Kim M; Lee S; Kim IS; Lee CH; Shin HM; Kim HR; Oh MD
    J Med Virol; 2023 Feb; 95(2):e28558. PubMed ID: 36755360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.
    Lu BN; Zhu KL; Cui XM; Yao L; Wang XJ; Wang GL; Duan LJ; Qian A; Ma MJ
    Clin Immunol; 2022 Nov; 244():109103. PubMed ID: 36049602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron (B.1.1.529) BA.1 or BA.2-related effects on immune responses in previously naïve versus imprinted individuals: immune imprinting as an advantage in the humoral immune response against novel variants.
    Sonnleitner ST; Walder S; Knabl L; Poernbacher R; Tschurtschenthaler T; Hinterbichler E; Sonnleitner S; Muehlmann V; Posch W; Walder G
    Front Immunol; 2023; 14():1165769. PubMed ID: 37256137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.
    Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Waterworth R; Umviligihozo G; Ennis S; Young L; Dong W; Kirkby D; Burns L; Leung V; Holmes DT; DeMarco ML; Simons J; Matic N; Montaner JSG; Brumme CJ; Prystajecky N; Niikura M; Lowe CF; Romney MG; Brockman MA; Brumme ZL
    Front Immunol; 2022; 13():947021. PubMed ID: 36148225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
    Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
    mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
    Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
    Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Speckmaier S; Barad E; Moran-Garcia N; Datwani S; Duncan MC; Kalikawe R; Ennis S; Young L; Ganase B; Omondi FH; Umviligihozo G; Dong W; Toy J; Sereda P; Burns L; Costiniuk CT; Cooper C; Anis AH; Leung V; Holmes D; DeMarco ML; Simons J; Hedgcock M; Prystajecky N; Lowe CF; Romney MG; Barrios R; Guillemi S; Brumme CJ; Montaner JSG; Hull M; Harris M; Niikura M; Brockman MA; Brumme ZL
    AIDS; 2023 Apr; 37(5):709-721. PubMed ID: 36545783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses.
    Chen Y; Song W; Li C; Wang J; Liu F; Ye Z; Ren P; Tong Y; Li J; Ou Z; Lee AC; Cai JP; Wong BH; Chan JF; Yuen KY; Zhang AJ; Chu H
    EBioMedicine; 2023 Mar; 89():104485. PubMed ID: 36857860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.
    Mu X; Cohen CA; Leung D; Rosa Duque JS; Cheng SMS; Chung Y; Wong HHW; Lee AMT; Li WY; Tam IYS; Lam JHY; Lee DHL; Chan SM; Tsang LCH; Chan KCK; Li JKC; Luk LLH; Chaothai S; Kwan KKH; Chu NC; Mori M; Jeevan T; Kandeil A; Webby RJ; Tu W; Valkenburg SA; Peiris M; Lau YL
    Signal Transduct Target Ther; 2022 Dec; 7(1):397. PubMed ID: 36517469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.
    Garcia-Valtanen P; Hope CM; Masavuli MG; Yeow AEL; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Bouras G; Gummow J; Ferguson C; O'Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Kok-Lim C; Beard MR; Weiskopf D; Sette A; Turville SG; Bull RA; Barry SC; Grubor-Bauk B
    Cell Rep Med; 2022 Jun; 3(6):100651. PubMed ID: 35654046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and host immunity responses of SARS-CoV-2 Omicron variant BA.2 with deletion of ORF7a, ORF7b and ORF8.
    Tang Z; Yu P; Guo Q; Chen M; Lei Y; Zhou L; Mai W; Chen L; Deng M; Kong W; Niu C; Xiong X; Li W; Chen C; Lai C; Wang Q; Li B; Ji T
    Virol J; 2023 May; 20(1):106. PubMed ID: 37248496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
    Mwimanzi F; Lapointe HR; Cheung PK; Sang Y; Yaseen F; Kalikawe R; Datwani S; Burns L; Young L; Leung V; Ennis S; Brumme CJ; Montaner JSG; Dong W; Prystajecky N; Lowe CF; DeMarco ML; Holmes DT; Simons J; Niikura M; Romney MG; Brumme ZL; Brockman MA
    Open Forum Infect Dis; 2023 Mar; 10(3):ofad073. PubMed ID: 36910697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.